Companies Cryptocurrencies
Innoviva Inc
Innoviva Inc
Exchange: Nasdaq Global Select
IPO Date: 05/10/2004
CEO: Mr. Michael Aguiar
Biotechnology Healthcare 🔗
  • INVA
  • 14.76
  • 1028751360
    market cap
  • -0.2699995
If you bought

shares of Innoviva Inc (INVA) on
You would have made
Old Price $12 Current Price $12

Innoviva, Inc. is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. The company is headquartered in Brisbane California, California and currently employs 6 full-time employees. The company focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.

Address: 2000 Sierra Point Pkwy Ste 500 Brisbane California CALIFORNIA

Stay updated.